Wiser about Scientific research

Sarcoidosis is a complex disease and much concerning this disease is still unknown. It can be difficult to diagnose patients. In some cases it is necessary to diagnose someone using biopsies, to determine the presence of granulomas under the microscope, with 100% certainty. However, sometimes this biopsy is considered to difficult or to dangerous. Think about obtaining brain- or nerve tissue in case of involvement of the nervous system (neurosarcoidosis) in some, but not all cases. Furthermore, not all patient respond wel to treatment. Especially in some rare manifestations of the disease this has not been investigated yet. To understand the disease better we are conducting scientific research of chronic inflammatory disorders, like sarcoidosis. We hope to collect more knowledge about this disease to ultimately improve patient care.

Scientific research

Recent publications

Off-labelgebruik van biologicals voor zeldzame immunologische aandoeningen

Anne Musters, Amira Assaf, Dominique L.P. Baeten en Sander W. Tas Patients with serious, immune-mediated inflammatory diseases (IMID's), like sarcoidosis, are increasingly treated with biologicals. Because research in these rare diseases is often very difficult, it is not known in all cases what the effects of the treatment are. In this article we elaborate on the RUBRIC-registry, in which we registrate the efficacy and the safety of these agents.

How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?: Making the right clinical decisions for rare diseases with the right tools.

Anne Musters en Sander W. Tas This article is an editorial in the scientific journal 'Rheumatology'. Evaluating the effects and safety of modern treatment agents which treat rare diseases can be complex, because it can be difficult to properly investigate them in a qualitative clinical trial due to the low number of patients with this disease. Therefore, it is important to adequately describe the effects of these treatments. This article suggests the five domains of the 'Rare IMID Disease Activity Score' (RIDAS).

More recent publications

Research groups

Neurosarcoïdose - Neuroinfecties AmsterdamVasculitiscentrum AMC